Who Owns OneOncology?

OneOncology operates within Cencora's corporate responsibility framework. As a healthcare services company, OneOncology's sustainability and ethics considerations center on patient care quality, data privacy, healthcare equity, and responsible business operations.

OneOncology's technology platforms enable paperless operations, reducing the environmental impact of traditional healthcare documentation. The Oncology Quality Hub facilitates electronic data collection and reporting, eliminating paper waste across partner practices. The platform's telehealth and care coordination capabilities also reduce patient travel requirements for specialized oncology care.

OneOncology maintains strict data privacy and security protocols for patient health information. The platform complies with HIPAA regulations and leverages Cencora's security infrastructure. The ethical use of patient data for quality improvement and research is an ongoing consideration in the platform's operations.

OneOncology supports community oncology care by making specialized cancer treatment more accessible in local communities. The platform enables independent oncology practices to compete with larger hospital systems, bringing quality cancer care to communities that might otherwise lose local oncology services. This includes underserved and rural areas where hospital-based oncology centers may not be accessible.

OneOncology is not certified as a B Corporation. The brand has not published independent carbon neutrality commitments or specific environmental certifications. Sustainability efforts are limited to operational efficiency initiatives and integration with Cencora's broader corporate responsibility programs.

OneOncology's Oncology Quality Hub received approval from the Centers for Medicare and Medicaid Services (CMS) as both a Qualified Clinical Data Registry (QCDR) and a Qualified Registry (QR) in 2024. This approval demonstrates OneOncology's ability to meet rigorous federal standards for collecting and submitting clinical data as part of CMS's Quality Payment Program.

OneOncology partner practices achieved an average MIPS score of 96 for the 2023 reporting period, a 13 percent improvement year over year. This performance reflects the platform's effectiveness in helping practices optimize quality metrics and achieve strong results in CMS quality payment programs.

In 2024, OneOncology highlighted research contributions from investigators at partner practices through 13 oral and poster presentations at the ASCO Annual Meeting. This level of research output from a community oncology platform demonstrates the platform's commitment to advancing oncology research in community practice settings.

OneOncology has been recognized by healthcare industry analysts as the fastest growing platform for independent oncology practices. The platform's rapid expansion from 220 providers at the time of Cencora's acquisition in 2023 to over 1,000 providers by 2024 has been noted in healthcare industry coverage.

OneOncology has not been subject to major product safety recalls or regulatory enforcement actions. The platform maintains a relatively clean public record. However, the company faces ongoing challenges typical of a rapidly growing healthcare services organization in a complex regulatory environment.

OneOncology operates in a highly regulated healthcare environment. The platform must maintain compliance with pharmacy regulations, healthcare compliance requirements, and evolving industry standards across multiple jurisdictions. The complexity of healthcare regulation creates ongoing compliance risk, particularly as the platform expands into new states and practice settings.

Following Cencora's majority stake acquisition in 2023 and the announced full acquisition in December 2025, OneOncology faces integration challenges. Combining OneOncology's physician-led culture with Cencora's corporate structure requires careful management to maintain the clinical autonomy and practice independence that are central to OneOncology's value proposition.

The healthcare industry is experiencing significant consolidation, and OneOncology's growth through practice acquisition and partnership creates potential conflicts of interest. Some healthcare advocates have raised concerns about the consolidation of independent practices under corporate ownership, even when the stated goal is to preserve independence.

OneOncology handles sensitive patient health data and must maintain strict compliance with HIPAA and other data protection regulations. As the platform grows and integrates with Cencora's broader data infrastructure, the risk surface for data privacy and security expands. The company must continuously invest in data security to protect patient information.